ArticleCancers2022

Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.

Shigeo Shimose et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.